Morgan Stanley Maintains Underweight on Integra Lifesciences, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri has maintained an 'Underweight' rating on Integra Lifesciences (NASDAQ:IART) and lowered the price target from $44 to $37.
October 26, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an 'Underweight' rating on Integra Lifesciences and lowered the price target from $44 to $37.
The 'Underweight' rating maintained by Morgan Stanley indicates a negative outlook for Integra Lifesciences. The lowering of the price target from $44 to $37 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100